RUDNICK SETH 4

4 · G1 Therapeutics, Inc. · Filed Dec 4, 2018

Form 4

Period: 2018-12-04

Director

Transactions

Exercise/Conversion
Stock Options (Right to Buy)
2018-12-04−607→ 0 total
Exercise: $0.39Exp: 2024-01-21→ Common Stock (607 underlying)
Exercise/Conversion
Common Stock
2018-12-04$0.39/sh+607$237→ 607 total
Exercise/Conversion
Common Stock
2018-12-04$0.39/sh+9,393$3,663→ 10,000 total
Sale
Common Stock
2018-12-04$39.31/sh−9,884$388,506→ 116 total
Sale
Common Stock
2018-12-04$40.00/sh−116$4,640→ 0 total
Exercise/Conversion
Stock Options (Right to Buy)
2018-12-04−9,393→ 7,969 total
Exercise: $0.39Exp: 2024-07-11→ Common Stock (9,393 underlying)

Holdings

Footnotes (4)

[F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price represents the weighted average price with a low of $38.99 and a high of $39.545. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
[F3]These shares are held in the Seth A. Rudnick 2014 GST Trust U/A Dated 03/01/2014 (the "Trust") for the benefit of the Reporting Person's heirs. The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
[F4]All shares underlying this option have vested.

Documents

1 file